文献速递肝病

非选择性β受体阻滞剂治疗中血管性血友病因子下降提示肝硬化失代偿患者预后改善

Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-07-10

本研究为回顾性分析,纳入159例临床稳定的失代偿期肝硬化患者,在非选择性β受体阻滞剂(NSBB)治疗前后配对评估肝静脉压力梯度(HVPG)和血管性血友病因子(VWF)。VWF应答者(VWF下降≥5%)相比非应答者,炎症指标下降更明显,HVPG应答率相似,且进一步失代偿、慢加急性肝衰竭(ACLF)和肝病相关死亡风险显著降低。

要点

  • NSBB治疗中VWF下降≥5%的失代偿期肝硬化患者,进一步失代偿、ACLF和死亡风险更低。
  • VWF应答反映NSBB的抗炎作用,与细菌易位/炎症指标变化相关,而非HVPG变化。
  • VWF应答者平均动脉压下降更轻,提示全身血管扩张改善。

核心结论

  • NSBB治疗中VWF下降反映抗炎活性,与全身血流动力学不良反应更轻相关,并独立关联进一步失代偿、ACLF和死亡风险降低。
  • VWF应答可能区分能从NSBB治疗中获益、预后良好的失代偿患者与预后不良患者。

研究设计与样本

  • 回顾性分析,纳入159例临床稳定(无急性失代偿)的失代偿期肝硬化患者,均在接受NSBB治疗前后进行配对HVPG/VWF评估。
  • 根据VWF下降≥5%将患者分为VWF应答者(61%)和VWF非应答者。

主要发现

  • VWF应答者降钙素原下降更明显,而HVPG应答率相似。
  • NSBB相关的VWF变化与细菌易位/炎症指标(脂多糖结合蛋白、C反应蛋白、降钙素原)的动态相关,而非HVPG变化。
  • VWF应答者平均动脉压下降更轻,提示全身血管扩张改善。

临床怎么用

  • 对于接受NSBB治疗的失代偿期肝硬化患者,监测VWF变化可能有助于识别治疗获益和预后良好的患者。
  • VWF下降≥5%可作为NSBB抗炎效应和预后改善的潜在生物标志物。

局限性

  • 回顾性分析设计。
  • 样本量有限(159例)。
  • VWF应答定义(下降≥5%)需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nonselective beta blockers (NSBBs) exert beneficial effects beyond lowering hepatic venous pressure gradient (HVPG), which may be particularly relevant in patients with decompensated cirrhosis (DC), in whom bacterial translocation and bacterial-induced systemic inflammation drive the development of complications such as acute-on-chronic liver failure (ACLF). We evaluated whether NSBB-related changes in von Willebrand factor (VWF) may serve as a biomarker for these effects. METHODS: In this retrospective analysis, 159 prospectively characterized patients with clinically stable DC (ie, without acute decompensation) who underwent paired HVPG/VWF assessments before/on NSBB therapy were classified as 'VWF-responders' (as defined by a ≥5% decrease in VWF) versus 'VWF-non-responders.' RESULTS: There were no major differences in baseline characteristics between VWF-responders (61%) and VWF-non-responders. VWF-responders showed more pronounced decreases in inflammation (procalcitonin), whereas rates of HVPG-response were similar. In line, NSBB-related changes in VWF correlated with the dynamics of bacterial translocation/inflammation (lipopolysaccharide-binding protein, C-reactive protein, and procalcitonin), rather than those of HVPG. Interestingly, VWF-responders also showed less pronounced NSBB-related decreases in mean arterial pressure, suggesting an amelioration of systemic vasodilatation. Finally, VWF-response was associated with decreased risks of further decompensation (adjusted hazard ratio [aHR], 0.555; 95% confidence interval [CI], 0.337-0.912; P = .020), ACLF (aHR, 0.302; 95% CI, 0.126-0.721; P = .007), and liver-related death (aHR, 0.332; 95% CI, 0.179-0.616; P < .001) in Cox regression models adjusted for prognostic factors including changes in HVPG. CONCLUSIONS: Decreases in VWF upon NSBB therapy reflect their anti-inflammatory activity, are accompanied by less pronounced adverse effects on systemic hemodynamics, and are independently associated with a decreased risk of further decompensation, ACLF, and death. VWF-response may discriminate between decompensated patients who benefit from NSBB treatment and have a favorable prognosis versus patients with poor outcomes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Jachs M, Hartl L, Simbrunner B, et al. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. Clin Gastroenterol Hepatol. 2021. PMID: 34256145. doi:10.1016/j.cgh.2021.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。